Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark L Heaney

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Blood Advances|September 11, 2020
ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trialStephen T Oh, Moshe Talpaz, Aaron T Gerds, et al.
Haematologica|October 21, 2017
Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasmsGabriela S Hobbs, Amritha Varshini Hanasoge Somasundara, Maria Kleppe, et al.
Blood|February 16, 2010
Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosisPriya Koppikar, Omar Abdel-Wahab, Cyrus Hedvat, et al.
Blood Advances|December 20, 2018
Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasmsRaajit K Rampal, John O Mascarenhas, Heidi E Kosiorek, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 22, 2013
Myeloid growth factorsJeffrey Crawford, James Armitage, Lodovico Balducci, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 6, 2007
Myeloid growth factors. Clinical practice guidelines in oncologyJeffrey Crawford, Betsy Althaus, James Armitage, et al.
Nature Medicine|December 7, 2021
Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trialJason Gotlib, Andreas Reiter, Deepti H Radia, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 30, 2009
Myeloid growth factorsJeffrey Crawford, James Armitage, Lodovico Balducci, et al.
Blood|March 19, 2020
Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular eraGaurav Goyal, Mark L Heaney, Matthew Collin, et al.
Blood Advances|October 26, 2020
Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phaseJohn O Mascarenhas, Raajit K Rampal, Heidi E Kosiorek, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Blood Advances|September 11, 2020
ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trialStephen T Oh, Moshe Talpaz, Aaron T Gerds, et al.
Haematologica|October 21, 2017
Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasmsGabriela S Hobbs, Amritha Varshini Hanasoge Somasundara, Maria Kleppe, et al.
Blood|February 16, 2010
Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosisPriya Koppikar, Omar Abdel-Wahab, Cyrus Hedvat, et al.
Blood Advances|December 20, 2018
Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasmsRaajit K Rampal, John O Mascarenhas, Heidi E Kosiorek, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 22, 2013
Myeloid growth factorsJeffrey Crawford, James Armitage, Lodovico Balducci, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 6, 2007
Myeloid growth factors. Clinical practice guidelines in oncologyJeffrey Crawford, Betsy Althaus, James Armitage, et al.
Nature Medicine|December 7, 2021
Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trialJason Gotlib, Andreas Reiter, Deepti H Radia, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 30, 2009
Myeloid growth factorsJeffrey Crawford, James Armitage, Lodovico Balducci, et al.
Blood|March 19, 2020
Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular eraGaurav Goyal, Mark L Heaney, Matthew Collin, et al.
Blood Advances|October 26, 2020
Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phaseJohn O Mascarenhas, Raajit K Rampal, Heidi E Kosiorek, et al.
Pageof 5